CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders
نویسندگان
چکیده
منابع مشابه
CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders
The differentiation between multiple system atrophy (MSA) and Parkinson's disease (PD) is difficult, particularly in early disease stages. Therefore, we aimed to evaluate the diagnostic value of neurofilament light chain (NFL), fms-like tyrosine kinase ligand (FLT3L), and total tau protein (t-tau) in cerebrospinal fluid (CSF) as biomarkers to discriminate MSA from PD. Using commercially availab...
متن کاملCSF neurofilament light chain reflects corticospinal tract degeneration in ALS
OBJECTIVE Diffusion tensor imaging (DTI) is sensitive to white matter tract pathology. A core signature involving the corticospinal tracts (CSTs) has been identified in amyotrophic lateral sclerosis (ALS). Raised neurofilament light chain protein (NfL) in cerebrospinal fluid (CSF) is thought to reflect axonal damage in a range of neurological disorders. The relationship between these two measur...
متن کاملCSF α-synuclein does not differentiate between parkinsonian disorders
Differentiating between Parkinson's disease (PD) and atypical Parkinsonism (AP) is clinically relevant but challenging. A timely and correct diagnosis might result in better targeted treatment strategies, adequate patient counseling, and early recognition of disease-specific complications. We aimed to investigate whether cerebrospinal fluid (CSF) concentrations of α-synuclein are of additional ...
متن کاملNeurofilament light chain
Objective: To test blood and CSF neurofilament light chain (NfL) levels in relation to disease progression and survival in amyotrophic lateral sclerosis (ALS). Methods: Using an electrochemiluminescence immunoassay, NfL levels were measured in samples from 2 cohorts of patients with sporadic ALS and healthy controls, recruited in London (ALS/control, plasma: n 5 103/42) and Oxford (ALS/control,...
متن کاملFingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
OBJECTIVE We assessed CSF levels of the light chain subunit of neurofilaments (NfL) at baseline and after fingolimod therapy or placebo in patients with relapsing-remitting multiple sclerosis (RRMS). Changes in NfL levels were also correlated with relapse and MRI outcomes. METHODS CSF samples were available, at baseline and 12 months after treatment initiation, from a subset of 36 patients wi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Neurology
سال: 2015
ISSN: 1664-2295
DOI: 10.3389/fneur.2015.00091